Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype

Laboratory Investigation

Volumn 89, Issue 7, 2009, Pages 742-759

  Christophi, George P ^a   Panos, Michael ^a   Hudson, Chad A ^a   Christophi, Rebecca L ^a   Gruber, Ross C ^a   Mersich, Akos T ^a   Blystone, Scott D ^a   Jubelt, Burk ^a   Massa, Paul T ^a,b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Autoimmunity multiple sclerosis; Cytokines; Human; Inflammation; Macrophages; Transcription factors

Indexed keywords

ARGINASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; PROTEIN TYROSINE PHOSPHATASE SHP 1; STAT1 PROTEIN; STAT6 PROTEIN; TOLL LIKE RECEPTOR;

ADULT; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DEMYELINATION; DNA BINDING; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; HUMAN; INFLAMMATION; MACROPHAGE; MALE; MULTIPLE SCLEROSIS; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEFICIENCY; PROTEIN DEPLETION; PROTEIN FUNCTION;

ADULT; BASE SEQUENCE; CASE-CONTROL STUDIES; CYTOKINES; DEMYELINATING DISEASES; DNA PRIMERS; FEMALE; GENE EXPRESSION; HUMANS; INFLAMMATION; MACROPHAGES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NF-KAPPA B; PHENOTYPE; PROMOTER REGIONS, GENETIC; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; RNA, MESSENGER; RNA, SMALL INTERFERING; STAT1 TRANSCRIPTION FACTOR; STAT6 TRANSCRIPTION FACTOR;

EID: 67649833763     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2009.32     Document Type: Article

References (134)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000;343:938-952.
2. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717.
3. Kornek B, Lassmann H. Neuropathology of multiple sclerosis-new concepts. Brain Res Bull 2003;61:321-326
4. Bruck W, Sommermeier N, Bergmann M, et al. Macrophages in multiple sclerosis. Immunobiology 1996;195:588-600.
5. Trebst C, Sorensen TL, Kivisakk P, et al. CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am J Pathol 2001;159:1701-1710.
6. Lipton HL, Kumar AS, Trottier M. Theiler's virus persistence in the central nervous system of mice is associated with continuous viral replication and a difference in outcome of infection of infiltrating macrophages versus oligodendrocytes. Virus Res 2005;111:214-223.
7. Hendriks JJ, Teunissen CE, de Vries HE, et al. Macrophages and neurodegeneration. Brain Res Brain Res Rev 2005;48:185-195.
8. Benveniste EN. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med 1997;75:165-173.
9. Christophi GP, Hudson CA, Panos M, et al. Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 in virus-induced demyelinating disease. J Virol 2009;83:522-539.
10. Templeton SP, Kim TS, O'Malley K, et al. Maturation and localization of macrophages and microglia during infection with a neurotropic murine coronavirus. Brain Pathol 2008;18:40-51.
11. Hiremath MM, Saito Y, Knapp GW, et al. Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice. J Neuroimmunol 1998;92:38-49.
12. Breij EC, Brink BP, Veerhuis R, et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol 2008;63:16-25.
13. Dogan RN, Karpus WJ. Chemokines and chemokine receptors in autoimmune encephalomyelitis as a model for central nervous system inflammatory disease regulation. Front Biosci 2004;9: 1500-1505.
14. Ubogu EE, Cossoy MB, Ransohoff RM. The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci 2006;27:48-55.
15. Rodriguez M. Effectors of demyelination and remyelination in the CNS: implications for multiple sclerosis. Brain Pathol 2007;17:219-229.
16. Scarisbrick IA, Linbo R, Vandell AG, et al. Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biol Chem 2008;389:739-745.
17. Scarisbrick IA, Blaber SI, Lucchinetti CF, et al. Activity of a newly identified serine protease in CNS demyelination. Brain 2002;125(Part 6):1283-1296.
18. Karpus WJ, Kennedy KJ, Fife BT, et al. Anti-CCL2 treatment inhibits Theiler's murine encephalomyelitis virus-induced demyelinating disease. J Neurovirol 2006;12:251-261.
19. Eggert M, Goertsches R, Seeck U, et al. Changes in the activation level of NF-kappa B in lymphocytes of MS patients during glucocorticoid pulse therapy. J Neurol Sci 2008;264:145-150.
20. Gobin SJ, Montagne L, Van Zutphen M, et al. Upregulation of transcription factors controlling MHC expression in multiple sclerosis lesions. Glia 2001;36:68-77.
21. Frisullo G, Angelucci F, Caggiula M, et al. pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsingremitting multiple sclerosis patients correlates with disease activity. J Neurosci Res 2006;84:1027-1036.
22. Feng X, Petraglia AL, Chen M, et al. Low expression of interferonstimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol 2002;129:205-215.
23. Zeis T, Graumann U, Reynolds R, et al. Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. Brain 2008;131(Part 1):288-303.
24. Cannella B, Raine CS. Multiple sclerosis: cytokine receptors on oligodendrocytes predict innate regulation. Ann Neurol 2004;55 :46-57.
25. Christophi GP, Hudson CA, Gruber RC, et al. SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients. Lab Invest 2008;88:243-255.
26. Massa PT, Wu C. Increased inducible activation of NF-kappaB and responsive genes in astrocytes deficient in the protein tyrosine phosphatase SHP-1. J Interferon Cytokine Res 1998;18:499-507.
27. Khaled AR, Butfiloski EJ, Sobel ES, et al. Functional consequences of the SHP-1 defect in motheaten viable mice: role of NF-kappa B. Cell Immunol 1998;185:49-58.
28. Croker BA, Lawson BR, Berger M, et al. Inflammation and autoimmunity caused by a SHP1 mutation depend on IL-1, MyD88, and a microbial trigger. Proc Natl Acad Sci USA 2008;105:15028-15033.
29. David M, Chen HE, Goelz S, et al. Differential regulation of the alpha/ beta interferon-stimulated Jak/Stat pathway by the SH2 domaincontaining tyrosine phosphatase SHPTP1. Mol Cell Biol 1995;15: 7050-7058.
30. Massa PT, Wu C. The role of protein tyrosine phosphatase SHP-1 in the regulation of IFN-gamma signaling in neural cells. J Immunol 1996;157:5139-5144.
31. Bonaparte KL, Hudson CA, Wu C, et al. Inverse regulation of inducible nitric oxide synthase (iNOS) and arginase I by the protein tyrosine phosphatase SHP-1 in CNS glia. Glia 2006;53:827-835.
32. Hanson EM, Dickensheets H, Qu CK, et al. Regulation of the dephosphorylation of Stat6. Participation of Tyr-713 in the interleukin-4 receptor alpha, the tyrosine phosphatase SHP-1, and the proteasome. J Biol Chem 2003;278:3903-3911.
33. Huang Z, Coleman JM, Su Y, et al. SHP-1 regulates STAT6 phosphorylation and IL-4-mediated function in a cell type-specific manner. Cytokine 2005;29:118-124.
34. Kamata T, Yamashita M, Kimura M, et al. src homology 2 domaincontaining tyrosine phosphatase SHP-1 controls the development of allergic airway inflammation. J Clin Invest 2003;111:109-119.
35. Massa PT, Saha S, Wu C, et al. Expression and function of the protein tyrosine phosphatase SHP-1 in oligodendrocytes. Glia 2000;29:376-385.
36. Massa PT, Wu C, Fecenko-Tacka K. Dysmyelination and reduced myelin basic protein gene expression by oligodendrocytes of SHP-1- deficient mice. J Neurosci Res 2004;77:15-25.
37. Massa PT, Ropka SL, Saha S, et al. Critical role for protein tyrosine phosphatase SHP-1 in controlling infection of central nervous system glia and demyelination by Theiler's murine encephalomyelitis virus. J Virol 2002;76:8335-8346.
38. Deng C, Minguela A, Hussain RZ, et al. Expression of the tyrosine phosphatase SRC homology 2 domain-containing protein tyrosine phosphatase 1 determines T cell activation threshold and severity of experimental autoimmune encephalomyelitis. J Immunol 2002; 168:4511-4518.
39. Wasserman HA, Beal CD, Zhang Y, et al. MHC variant peptidemediated anergy of encephalitogenic T cells requires SHP-1. J Immunol 2008;181:6843-6849.
40. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50: 121-127.
41. De Nichilo MO, Burns GF. Granulocyte-macrophage and macrophage colony-stimulating factors differentially regulate alpha v integrin expression on cultured human macrophages. Proc Natl Acad Sci USA 1993;90:2517-2521.
42. Blystone SD, Graham IL, Lindberg FP, et al. Integrin alpha v beta 3 differentially regulates adhesive and phagocytic functions of the fibronectin receptor alpha 5 beta 1. J Cell Biol 1994;127:1129-1137.
43. Christophi GP, Hudson CA, Gruber R, et al. Promoter-specific induction of the phosphatase SHP-1 by viral infection and cytokines in CNS glia. J Neurochem 2008;105:2511-2523.
44. Krissansen GW, Elliott MJ, Lucas CM, et al. Identification of a novel integrin beta subunit expressed on cultured monocytes (macrophages). Evidence that one alpha subunit can associate with multiple beta subunits. J Biol Chem 1990;265:823-830.
45. Christophi GP, Isackson PJ, Blaber S, et al. Distinct promoters regulate tissue-specific and differential expression of kallikrein 6 in CNS demyelinating disease. J Neurochem 2004;91:1439-1449.
46. Renard P, Ernest I, Houbion A, et al. Development of a sensitive multiwell colorimetric assay for active NFkappaB. Nucleic Acids Res 2001;29:E21.
47. Zhu L, Zou W, Yu C, et al. Human recombinant PLD2 can repress p65 activity of guinea pigs of chronic asthma in vivo. Cell Mol Immunol 2006;3:307-310.
48. Sun J, Ramnath RD, Tamizhselvi R, et al. Neurokinin A engages neurokinin-1 receptor to induce NF-kappaB-dependent gene expression in murine macrophages: implications of ERK1/2 and PI 3-kinase/Akt pathways. Am J Physiol Cell Physiol 2008;295: C679-C691.
49. Hudson CA, Christophi GP, Gruber RC, et al. Induction of IL-33 expression and activity in central nervous system glia. J Leukoc Biol 2008;84:631-643.
50. Imhof BA, Aurrand-Lions M. Adhesion mechanisms regulating the migration of monocytes. Nat Rev Immunol 2004;4:432-444.
51. Kim CH, Qu CK, Hangoc G, et al. Abnormal chemokine-induced responses of immature and mature hematopoietic cells from motheaten mice implicate the protein tyrosine phosphatase SHP-1 in chemokine responses. J Exp Med 1999;190:681-690.
52. Forget G, Matte C, Siminovitch KA, et al. Regulation of the Leishmania-induced innate inflammatory response by the protein tyrosine phosphatase SHP-1. Eur J Immunol 2005;35:1906-1917.
53. Mazzone A, Ricevuti G. Leukocyte CD11/CD18 integrins: biological and clinical relevance. Haematologica 1995;80:161-175.
54. Meerschaert J, Furie MB. The adhesion molecules used by monocytes for migration across endothelium include CD11a/CD18, CD11b/CD18, and VLA-4 on monocytes and ICAM-1, VCAM-1, and other ligands on endothelium. J Immunol 1995;154:4099-4112.
55. Mazzone A, De Servi S, Mazzucchelli I, et al. Increased expression of CD11b/CD18 on phagocytes in ischaemic disease: a bridge between inflammation and coagulation. Eur J Clin Invest 1997;27:648-652.
56. Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005; 64:1336-1342.
57. Haque SJ, Harbor P, Tabrizi M, et al. Protein-tyrosine phosphatase Shp-1 is a negative regulator of IL-4- and IL-13-dependent signal transduction. J Biol Chem 1998;273:33893-33896.
58. Yetter A, Uddin S, Krolewski JJ, et al. Association of the interferondependent tyrosine kinase Tyk-2 with the hematopoietic cell phosphatase. J Biol Chem 1995;270:18179-18182.
59. Zhang Z, Jimi E, Bothwell AL. Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFRassociated factor 6 that regulates osteoclastogenesis. J Immunol 2003;171:3620-3626.
60. Bonetti B, Stegagno C, Cannella B, et al. Activation of NF-kappaB and c-jun transcription factors in multiple sclerosis lesions. Implications for oligodendrocyte pathology. Am J Pathol 1999;155:1433-1438.
61. Gveric D, Kaltschmidt C, Cuzner ML, et al. Transcription factor NFkappaB and inhibitor I kappaBalpha are localized in macrophages in active multiple sclerosis lesions. J Neuropathol Exp Neurol 1998; 57:168-178.
62. Zhao J, Brooks DM, Lurie DI. Lipopolysaccharide-activated SHP-1- deficient motheaten microglia release increased nitric oxide, TNFalpha, and IL-1beta. Glia 2006;53:304-312.
63. Wu L, Iwai M, Li Z, et al. Regulation of inhibitory protein-kappaB and monocyte chemoattractant protein-1 by angiotensin II type 2 receptor-activated Src homology protein tyrosine phosphatase-1 in fetal vascular smooth muscle cells. Mol Endocrinol 2004;18:666-678.
64. Thrall RS, Vogel SN, Evans R, et al. Role of tumor necrosis factor-alpha in the spontaneous development of pulmonary fibrosis in viable motheaten mutant mice. Am J Pathol 1997;151:1303-1310.
65. An H, Hou J, Zhou J, et al. Phosphatase SHP-1 promotes TLR- and RIGI- activated production of type I interferon by inhibiting the kinase IRAK1. Nat Immunol 2008;9:542-550.
66. Hudson CA, Christophi GP, Cao L, et al. Regulation of avoidant behaviors and pain by the anti-inflammatory tyrosine phosphatase SHP-1. Neuron Glia Biol 2006;2:235-246.
67. Wirnsberger G, Hebenstreit D, Posselt G, et al. IL-4 induces expression of TARC/CCL17 via two STAT6 binding sites. Eur J Immunol 2006;36:1882-1891.
68. Narikawa K, Misu T, Fujihara K, et al. CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis. J Neuroimmunol 2004;149:182-186.
69. Matsukura S, Stellato C, Georas SN, et al. Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism. Am J Respir Cell Mol Biol 2001;24:755-761.
70. Richens J, Fairclough L, Ghaemmaghami AM, et al. The detection of ADAM8 protein on cells of the human immune system and the demonstration of its expression on peripheral blood B cells, dendritic cells and monocyte subsets. Immunobiology 2007;212:29-38.
71. King NE, Zimmermann N, Pope SM, et al. Expression and regulation of a disintegrin and metalloproteinase (ADAM) 8 in experimental asthma. Am J Respir Cell Mol Biol 2004;31:257-265.
72. Amour A, Knight CG, English WR, et al. The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett 2002;524:154-158.
73. Xu L, Hilliard B, Carmody RJ, et al. Arginase and autoimmune inflammation in the central nervous system. Immunology 2003; 110:141-148.
74. Sorensen TL, Tani M, Jensen J, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999;103:807-815.
75. Simpson JE, Newcombe J, Cuzner ML, et al. Expression of the interferon-gamma-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions. Neuropathol Appl Neurobiol 2000;26:133-142.
76. Salmaggi A, Gelati M, Dufour A, et al. Expression and modulation of IFN-gamma-inducible chemokines (IP-10, Mig, and I-TAC) in human brain endothelium and astrocytes: possible relevance for the immune invasion of the central nervous system and the pathogenesis of multiple sclerosis. J Interferon Cytokine Res 2002;22:631-640.
77. Tanuma N, Sakuma H, Sasaki A, et al. Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis. Acta Neuropathol 2006;112:195-204.
78. Omari KM, John GR, Sealfon SC, et al. CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis. Brain 2005;128(Part 5):1003-1015.
79. Huang WX, Huang P, Hillert J. Increased expression of caspase-1 and interleukin-18 in peripheral blood mononuclear cells in patients with multiple sclerosis. Mult Scler 2004;10:482-487.
80. Chin YE, Kitagawa M, Kuida K, et al. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol 1997;17:5328-5337.
81. Furlan R, Martino G, Galbiati F, et al. Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J Immunol 1999;163:2403-2409.
82. Ahn KS, Aggarwal BB. Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann NY Acad Sci 2005;1056:218-233.
83. Quinones MP, Kalkonde Y, Estrada CA, et al. Role of astrocytes and chemokine systems in acute TNFalpha induced demyelinating syndrome: CCR2-dependent signals promote astrocyte activation and survival via NF-kappaB and Akt. Mol Cell Neurosci 2008;37:96-109.
84. Benoit M, Desnues B, Mege JL. Macrophage polarization in bacterial infections. J Immunol 2008;181:3733-3739.
85. Nguyen VT, Benveniste EN. IL-4-activated STAT-6 inhibits IFN-gammainduced CD40 gene expression in macrophages/microglia. J Immunol 2000;165:6235-6243.
86. Hamilton TA, Ohmori Y, Tebo JM, et al. Regulation of macrophage gene expression by pro- and anti-inflammatory cytokines. Pathobiology 1999;67:241-244.
87. Major J, Fletcher JE, Hamilton TA. IL-4 pretreatment selectively enhances cytokine and chemokine production in lipopolysaccharidestimulated mouse peritoneal macrophages. J Immunol 2002;168: 2456-2463.
88. Hesse M, Modolell M, La Flamme AC, et al. Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism. J Immunol 2001;167:6533-6544.
89. Bruck W, Porada P, Poser S, et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995;38:788-796.
90. van der Goes A, Boorsma W, Hoekstra K, et al. Determination of the sequential degradation of myelin proteins by macrophages. J Neuroimmunol 2005;161:12-20.
91. Raivich G, Banati R. Brain microglia and blood-derived macrophages: molecular profiles and functional roles in multiple sclerosis and animal models of autoimmune demyelinating disease. Brain Res Brain Res Rev 2004;46:261-281.
92. Belperio JA, Dy M, Murray L, et al. The role of the Th2 CC chemokine ligand CCL17 in pulmonary fibrosis. J Immunol 2004;173: 4692-4698.
93. Wenzel J, Henze S, Worenkamper E, et al. Role of the chemokine receptor CCR4 and its ligand thymus- and activation-regulated chemokine/CCL17 for lymphocyte recruitment in cutaneous lupus erythematosus. J Invest Dermatol 2005;124:1241-1248.
94. Menzies-Gow A, Ying S, Sabroe I, et al. Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers. J Immunol 2002;169:2712-2718.
95. Scarisbrick IA. The multiple sclerosis degradome: enzymatic cascades in development and progression of central nervous system inflammatory disease. Curr Top Microbiol Immunol 2008;318: 133-175.
96. Ming X, Li W, Maeda Y, et al. Caspase-1 expression in multiple sclerosis plaques and cultured glial cells. J Neurol Sci 2002;197:9-18.
97. Karni A, Abraham M, Monsonego A, et al. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol 2006;177:4196-4202.
98. Huang YM, Xiao BG, Ozenci V, et al. Multiple sclerosis is associated with high levels of circulating dendritic cells secreting proinflammatory cytokines. J Neuroimmunol 1999;99:82-90.
99. Link J, Soderstrom M, Olsson T, et al. Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis. Ann Neurol 1994;36:379-386.
100. Link H. The cytokine storm in multiple sclerosis. Mult Scler 1998; 4:12-15.
101. Hermans G, Stinissen P, Hauben L, et al. Cytokine profile of myelin basic protein-reactive T cells in multiple sclerosis and healthy individuals. Ann Neurol 1997;42:18-27.
102. Rohowsky-Kochan C, Molinaro D, Cook SD. Cytokine secretion profile of myelin basic protein-specific T cells in multiple sclerosis. Mult Scler 2000;6:69-77.
103. Ochi H, Osoegawa M, Wu XM, et al. Increased IL-13 but not IL-5 production by CD4-positive T cells and CD8-positive T cells in multiple sclerosis during relapse phase. J Neurol Sci 2002;201: 45-51.
104. Ozenci V, Kouwenhoven M, Huang YM, et al. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment. Clin Exp Immunol 2000;120:147-153.
105. Hohnoki K, Inoue A, Koh CS. Elevated serum levels of IFN-gamma, IL-4 and TNF-alpha/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage. J Neuroimmunol 1998;87:27-32.
106. Ishizu T, Osoegawa M, Mei FJ, et al. Intrathecal activation of the IL-17/ IL-8 axis in opticospinal multiple sclerosis. Brain 2005;128(Part 5): 988-1002.
107. Killestein J, Den Drijver BF, Van der Graaff WL, et al. Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease. Mult Scler 2001;7:145-150.
108. Christophi GP, Hudson CA, Panos M, et al. Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 in virus-induced demyelinating disease. J Virol 2009;83:522-539.
109. Kant AM, De P, Peng X, et al. SHP-1 regulates Fcgamma receptormediated phagocytosis and the activation of RAC. Blood 2002;100:1852-1859.
110. Oldenborg PA, Gresham HD, Lindberg FP. CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis. J Exp Med 2001;193:855-862.
111. Huang ZY, Hunter S, Kim MK, et al. The effect of phosphatases SHP-1 and SHIP-1 on signaling by the ITIM- and ITAM-containing Fcgamma receptors FcgammaRIIB and FcgammaRIIA. J Leukoc Biol 2003;73:823-829.
112. Banville D, Stocco R, Shen SH. Human protein tyrosine phosphatase 1C (PTPN6) gene structure: alternate promoter usage and exon skipping generate multiple transcripts. Genomics 1995;27:165-173.
113. Tsui HW, Hasselblatt K, Martin A, et al. Molecular mechanisms underlying SHP-1 gene expression. Eur J Biochem 2002;269: 3057-3064.
114. Xu Y, Banville D, Zhao HF, et al. Transcriptional activity of the SHP-1 gene in MCF7 cells is differentially regulated by binding of NF-Y factor to two distinct CCAAT-elements. Gene 2001;269:141-153.
115. Oksenberg JR, Barcellos LF. Multiple sclerosis genetics: leaving no stone unturned. Genes Immun 2005;6:375-387.
116. Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007;357:851-862.
117. Karpuj MV, Steinman L, Oksenberg JR. Multiple sclerosis: a polygenic disease involving epistatic interactions, germline rearrangements and environmental effects. Neurogenetics 1997;1:21-28.
118. Asimakopoulos FA, Hinshelwood S, Gilbert JG, et al. The gene encoding hematopoietic cell phosphatase (SHP-1) is structurally and transcriptionally intact in polycythemia vera. Oncogene 1997; 14:1215-1222.
119. Yi TL, Cleveland JL, Ihle JN. Protein tyrosine phosphatase containing SH2 domains: characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12-p13. Mol Cell Biol 1992;12:836-846.
120. Zhang Q, Raghunath PN, Vonderheid E, et al. Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am J Pathol 2000;157:1137-1146.
121. Oka T, Yoshino T, Hayashi K, et al. Reduction of hematopoietic cellspecific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias: combination analysis with cDNA expression array and tissue microarray. Am J Pathol 2001;159:1495-1505.
122. Osawa T, Chong JM, Sudo M, et al. Reduced expression and promoter methylation of p16 gene in Epstein-Barr virus-associated gastric carcinoma. Jpn J Cancer Res 2002;93:1195-1200.
123. Muller K, Heller H, Doerfler W. Foreign DNA integration. Genomewide perturbations of methylation and transcription in the recipient genomes. J Biol Chem 2001;276:14271-14278.
124. de Bustros A, Nelkin BD, Silverman A, et al. The short arm of chromosome 11 is a 'hot spot' for hypermethylation in human neoplasia. Proc Natl Acad Sci USA 1988;85:5693-5697.
125. Mikovits JA, Young HA, Vertino P, et al. Infection with human immunodeficiency virus type 1 upregulates DNA methyltransferase, resulting in de novo methylation of the gamma interferon (IFNgamma) promoter and subsequent downregulation of IFN-gamma production. Mol Cell Biol 1998;18:5166-5177.
126. Amara K, Trimeche M, Ziadi S, et al. Presence of simian virus 40 DNA sequences in diffuse large B-cell lymphomas in Tunisia correlates with aberrant promoter hypermethylation of multiple tumor suppressor genes. Int J Cancer 2007;121:2693-2702.
127. Lipton HL, Liang Z, Hertzler S, et al. A specific viral cause of multiple sclerosis: one virus, one disease. Ann Neurol 2007;61:514-523.
128. Valinluck V, Sowers LC. Inflammation-mediated cytosine damage: a mechanistic link between inflammation and the epigenetic alterations in human cancers. Cancer Res 2007;67:5583-5586.
129. Valinluck V, Sowers LC. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res 2007;67:946-950.
130. Rouleau J, MacLeod AR, Szyf M. Regulation of the DNA methyltransferase by the Ras-AP-1 signaling pathway. J Biol Chem 1995;270:1595-1601.
131. Hmadcha A, Bedoya FJ, Sobrino F, et al. Methylation-dependent gene silencing induced by interleukin 1beta via nitric oxide production. J Exp Med 1999;190:1595-1604.
132. Araujo AQ, Silva MT. The HTLV-1 neurological complex. Lancet Neurol 2006;5:1068-1076.
133. Cheng J, Kydd AR, Nakase K, et al. Negative regulation of the SH2- homology containing protein-tyrosine phosphatase-1 (SHP-1) P2 promoter by the HTLV-1 Tax oncoprotein. Blood 2007;110:2110-2120.
134. Nakase K, Cheng J, Zhu Q, et al. Mechanisms of SHP-1 P2 promoter regulation in hematopoietic cells and its silencing in HTLV-1- transformed T cells. J Leukoc Biol 2009;85:165-174.